Cargando…

Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer

Modified FOLFIRINOX (mFFX) and Gemcitabine plus nab-paclitaxel (GnP) are effective first-line chemotherapies for unresectable advanced pancreatic cancer (APC); however, both lead to peripheral neuropathy (PN). Aims: To evaluate the impact of first-line mFFX-induced PN on the efficacy of second-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadaka, Shiori, Iwashita, Takuji, Fujii, Hironori, Kato-Hayashi, Hiroko, Ohata, Koichi, Uemura, Shinya, Shimizu, Masahito, Suzuki, Akio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572211/
https://www.ncbi.nlm.nih.gov/pubmed/36233762
http://dx.doi.org/10.3390/jcm11195895
_version_ 1784810556767600640
author Sadaka, Shiori
Iwashita, Takuji
Fujii, Hironori
Kato-Hayashi, Hiroko
Ohata, Koichi
Uemura, Shinya
Shimizu, Masahito
Suzuki, Akio
author_facet Sadaka, Shiori
Iwashita, Takuji
Fujii, Hironori
Kato-Hayashi, Hiroko
Ohata, Koichi
Uemura, Shinya
Shimizu, Masahito
Suzuki, Akio
author_sort Sadaka, Shiori
collection PubMed
description Modified FOLFIRINOX (mFFX) and Gemcitabine plus nab-paclitaxel (GnP) are effective first-line chemotherapies for unresectable advanced pancreatic cancer (APC); however, both lead to peripheral neuropathy (PN). Aims: To evaluate the impact of first-line mFFX-induced PN on the efficacy of second-line GnP in patients with APC. Methods: A database containing patients with APC was retrospectively analyzed to evaluate patients who received second-line GnP after first-line mFFX failure between September 2014 and January 2021. The efficacy and safety of GnP were compared between patients with PN ≥ Grade 2 (PN group) and PN ≤ Grade 1 (non-PN group) at the start of second-line GnP. Cox proportional hazards analysis was also performed to examine the effect on overall survival (OS) and time-to-treatment failure (TTF). Results: Fifty-nine patients (PN group, 18 patients; non-PN group, 41 patients) were included. Median OS and TTF in the PN versus non-PN group were 7.7 versus 5.7 months (p = 0.19) and 3.8 versus 2.7 months (p = 0.18), respectively. Multivariate analysis showed that PN (≥Grade 2) was not a significant factor affecting either OS (hazard ratio (HR) 0.66, 95% confidence interval [CI] 0.33–1.31, p = 0.24) or TTF (HR 0.71, 95% CI 0.38–1.33, p = 0.28). No significant difference was observed in the relative dose intensity of GEM or nab-PTX, and incidence of adverse events. Conclusions: mFFX-induced PN has little impact on the efficacy and safety of second-line GnP in patients with APC. Second-line GnP could be a possible treatment option regardless of the presence of PN.
format Online
Article
Text
id pubmed-9572211
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95722112022-10-17 Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer Sadaka, Shiori Iwashita, Takuji Fujii, Hironori Kato-Hayashi, Hiroko Ohata, Koichi Uemura, Shinya Shimizu, Masahito Suzuki, Akio J Clin Med Article Modified FOLFIRINOX (mFFX) and Gemcitabine plus nab-paclitaxel (GnP) are effective first-line chemotherapies for unresectable advanced pancreatic cancer (APC); however, both lead to peripheral neuropathy (PN). Aims: To evaluate the impact of first-line mFFX-induced PN on the efficacy of second-line GnP in patients with APC. Methods: A database containing patients with APC was retrospectively analyzed to evaluate patients who received second-line GnP after first-line mFFX failure between September 2014 and January 2021. The efficacy and safety of GnP were compared between patients with PN ≥ Grade 2 (PN group) and PN ≤ Grade 1 (non-PN group) at the start of second-line GnP. Cox proportional hazards analysis was also performed to examine the effect on overall survival (OS) and time-to-treatment failure (TTF). Results: Fifty-nine patients (PN group, 18 patients; non-PN group, 41 patients) were included. Median OS and TTF in the PN versus non-PN group were 7.7 versus 5.7 months (p = 0.19) and 3.8 versus 2.7 months (p = 0.18), respectively. Multivariate analysis showed that PN (≥Grade 2) was not a significant factor affecting either OS (hazard ratio (HR) 0.66, 95% confidence interval [CI] 0.33–1.31, p = 0.24) or TTF (HR 0.71, 95% CI 0.38–1.33, p = 0.28). No significant difference was observed in the relative dose intensity of GEM or nab-PTX, and incidence of adverse events. Conclusions: mFFX-induced PN has little impact on the efficacy and safety of second-line GnP in patients with APC. Second-line GnP could be a possible treatment option regardless of the presence of PN. MDPI 2022-10-06 /pmc/articles/PMC9572211/ /pubmed/36233762 http://dx.doi.org/10.3390/jcm11195895 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sadaka, Shiori
Iwashita, Takuji
Fujii, Hironori
Kato-Hayashi, Hiroko
Ohata, Koichi
Uemura, Shinya
Shimizu, Masahito
Suzuki, Akio
Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
title Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
title_full Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
title_fullStr Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
title_full_unstemmed Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
title_short Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
title_sort impact of first-line folfirinox-induced peripheral neuropathy on the efficacy of second-line gnp in patients with unresectable advanced pancreatic cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572211/
https://www.ncbi.nlm.nih.gov/pubmed/36233762
http://dx.doi.org/10.3390/jcm11195895
work_keys_str_mv AT sadakashiori impactoffirstlinefolfirinoxinducedperipheralneuropathyontheefficacyofsecondlinegnpinpatientswithunresectableadvancedpancreaticcancer
AT iwashitatakuji impactoffirstlinefolfirinoxinducedperipheralneuropathyontheefficacyofsecondlinegnpinpatientswithunresectableadvancedpancreaticcancer
AT fujiihironori impactoffirstlinefolfirinoxinducedperipheralneuropathyontheefficacyofsecondlinegnpinpatientswithunresectableadvancedpancreaticcancer
AT katohayashihiroko impactoffirstlinefolfirinoxinducedperipheralneuropathyontheefficacyofsecondlinegnpinpatientswithunresectableadvancedpancreaticcancer
AT ohatakoichi impactoffirstlinefolfirinoxinducedperipheralneuropathyontheefficacyofsecondlinegnpinpatientswithunresectableadvancedpancreaticcancer
AT uemurashinya impactoffirstlinefolfirinoxinducedperipheralneuropathyontheefficacyofsecondlinegnpinpatientswithunresectableadvancedpancreaticcancer
AT shimizumasahito impactoffirstlinefolfirinoxinducedperipheralneuropathyontheefficacyofsecondlinegnpinpatientswithunresectableadvancedpancreaticcancer
AT suzukiakio impactoffirstlinefolfirinoxinducedperipheralneuropathyontheefficacyofsecondlinegnpinpatientswithunresectableadvancedpancreaticcancer